 The primary objective of the study is to evaluate the activity of BDD in subjects with acute renal failure as measured by reversal of acute renal failureSecondary objectives tumor response complete and partial response To evaluate the safety of Bortezomib- Doxorubicin-Dexamethasone in this patient population to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on progression free survival to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on overall survival 